Literature DB >> 26078634

Veno-venous extracorporal membrane oxygenation in a deeply hypoxemic infant with persistent air leakages: The first successful pediatric veno-venous extracorporeal membrane oxygenation case report in Turkey.

Nilüfer Yalındağ Öztürk1, Koray Ak2, Nilgün Erkek3, Tolga Besci4, Selim İşbir2, Sinan Arsan2.   

Abstract

In severe respiratory failure, extracorporal membrane oxygenation support is life-saving, but it has been started to be used in pediatric intensive care units in our country very recently. Here, we present a five-month old girl who developed acute respiratory distress and air leakages following removal of a foreign body obstructing the airway. Mechanical ventilation only increased the air leaks and - despite drainage-resulted in hypoxemia, acidosis and finally cardiopulmonary arrest. Initiation of veno-venous (VV) ECMO improved oxygenation as well as hemodynamics. The patient was weaned off extracorporal membrane oxygenation support on the 7th day with improvement in the lung parenchyma and ceasing of the air leakages; she was discharged on the 27(th) day of her hospitalization without any neurologicalsequela. As far as we know, this patient is the first pediatric patient who was discharged with success after application of venovenous-extracorporal membrane oxygenation with a respiratory indication in a pediatric intensive care unit in our country. We think that similar patients who need extracorporal membrane oxygenation can be cured with close collaboration of specialists of cardiovascular surgery and pediatric intensive care, dedicated nurses and perfusionist support when necessary.

Entities:  

Keywords:  Pediatric intensive care unit; airway obstruction; extracorporal membrane oxygenation; pneumothorax; respiratory failure

Year:  2014        PMID: 26078634      PMCID: PMC4462272          DOI: 10.5152/tpa.2014.1172

Source DB:  PubMed          Journal:  Turk Pediatri Ars


  7 in total

Review 1.  A review of venovenous and venoarterial extracorporeal membrane oxygenation in neonates and children.

Authors:  S J Keckler; C A Laituri; D J Ostlie; S D St Peter
Journal:  Eur J Pediatr Surg       Date:  2009-09-10       Impact factor: 2.191

2.  UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. UK Collaborative ECMO Trail Group.

Authors: 
Journal:  Lancet       Date:  1996-07-13       Impact factor: 79.321

3.  Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.

Authors:  Stavros Petrou; Matthias Bischof; Charlotte Bennett; Diana Elbourne; David Field; Helena McNally
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

4.  Increased extracorporeal membrane oxygenation center case volume is associated with improved extracorporeal membrane oxygenation survival among pediatric patients.

Authors:  Tara Karamlou; Mina Vafaeezadeh; Andrea M Parrish; Gordon A Cohen; Karl F Welke; Lester Permut; D Michael McMullan
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-14       Impact factor: 5.209

5.  Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.

Authors:  Giles J Peek; Miranda Mugford; Ravindranath Tiruvoipati; Andrew Wilson; Elizabeth Allen; Mariamma M Thalanany; Clare L Hibbert; Ann Truesdale; Felicity Clemens; Nicola Cooper; Richard K Firmin; Diana Elbourne
Journal:  Lancet       Date:  2009-09-15       Impact factor: 79.321

6.  Extracorporeal life support experiences of a new congenital heart center in Turkey.

Authors:  Ersin Erek; Sertac Haydin; Burak Onan; Ismihan Selen Onan; Pinar Yazici; Ozgen Kocyigit; Cansaran Tanidir; Perihan Yivli; Ender Odemis; Mehmet Yeniterzi; Ihsan Bakir
Journal:  Artif Organs       Date:  2013-01       Impact factor: 3.094

7.  Extracorporeal Life Support Organization Registry Report 2012.

Authors:  Matthew L Paden; Steven A Conrad; Peter T Rycus; Ravi R Thiagarajan
Journal:  ASAIO J       Date:  2013 May-Jun       Impact factor: 2.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.